Apixaban in patients with atrial fibrillation: patient characteristics of the Latin America cohort from a multinational clinical trial
Value health
; 18(7): [A809], 2015.
Article
em En
| SES-SP, SESSP-IDPCPROD, SES-SP
| ID: biblio-1068370
Biblioteca responsável:
BR79.1
Localização: BR79.1
ABSTRACT
Patients with Atrial fibrillation (AF), have a five-fold increase in the risk of stroke. Treatment for AF include stroke prevention therapy. Vitamin K antagonists (VKAs) have shown to prevent stroke in AF patients. Apixaban, a novel oral direct factor Xa inhibitor was studied in AF patients whom VKA therapy was unsuitable. Apixaban demonstrated clinical benefit in stroke or systemic embolism reduction without impacting the risk of major bleeding or intracranial hemorrhage. Patient characteristics of the Latin America (LA) cohort and overall population are presented.
Buscar no Google
Coleções:
06-national
/
BR
Base de dados:
SES-SP
/
SESSP-IDPCPROD
Assunto principal:
Pacientes
/
Acidente Vascular Cerebral
/
América Latina
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Revista:
Value health
Ano de publicação:
2015
Tipo de documento:
Article